Moderna’s personalized cancer vaccine did not miss its Phase 3 primary endpoint. The stock still fell hard.
That apparent contradiction makes sense once the clinical result is separated from the expectations embedded in the share price.
What the Phase 3 trial actually showed
Merck and Moderna said the Phase 3 INTerpath-001 study enrolled 1,137 patients with completely resected stage IIB-IV melanoma. Intismeran autogene plus Keytruda reduced the risk of recurrence or death by 42% versus Keytruda alone, with a hazard ratio of 0.58 and p-value below 0.001.
The combination also reduced the risk of distant metastasis or death by 38%. Two-year recurrence-free survival was 82.2% with the combination versus 70.0% with Keytruda alone. Overall-survival data are not yet mature.
| Measure | Intismeran + Keytruda vs. Keytruda |
|---|---|
| Recurrence or death | 42% risk reduction (HR 0.58) |
| Distant metastasis or death | 38% risk reduction (HR 0.62) |
| Two-year recurrence-free survival | 82.2% vs. 70.0% |
| Overall survival | Not yet mature; favorable trend reported |
So why did MRNA fall?
The market had already repriced Moderna aggressively after the companies announced in August that the study had succeeded without releasing the detailed hazard ratios. Reuters reported that the stock had risen more than 500% during the year before the detailed readout and described the subsequent drop as a “sell-the-news” reaction.
In other words, the question was no longer simply whether the study was positive. Investors were comparing the magnitude and shape of the benefit with expectations that had risen alongside the share price.
The first six months complicate the headline
The prespecified analysis also showed that during the first six months, before completion of the intismeran immunization regimen, recurrence risk was essentially comparable with Keytruda alone. After six months, a prespecified sensitivity analysis showed a larger 58% reduction in recurrence or death.
That pattern may be biologically sensible for an individualized vaccine that takes time to generate an immune response, but it also means investors have more than one number to model rather than a single instantaneous treatment effect.
What matters next
The first question is regulatory timing. Merck and Moderna say they are engaging with regulators. The second is overall survival, which remains immature. The third — and likely the biggest valuation question — is whether the individualized neoantigen platform can reproduce meaningful efficacy in other tumor types.
Moderna says the broader INTerpath program includes nine Phase 2 and Phase 3 trials across several cancers, including three ongoing Phase 3 lung-cancer trials. If melanoma proves to be the first of several successful indications, the platform value can expand substantially. If the benefit is difficult to reproduce elsewhere, the melanoma success may be important medically without supporting the much larger platform expectations the stock had begun to price.
Sources
- Merck — detailed Phase 3 INTerpath-001 results
- Moderna — IR Insights recap of INTerpath-001
- Reuters — market reaction to the Phase 3 data
Markets & News distinguishes verified disclosures, reported market reaction and our analysis. This article may be updated as primary-source information changes.